Skip to search formSkip to main contentSkip to account menu

Femara

Known as: Femara®, Fémara, Novartis Brand of Letrozole 
National Institutes of Health

Related topics

Related topics

8 relations

Broader (5)

Antineoplastic AgentsEnzyme InhibitorsNitrilesTriazoles
CGS 20267letrozole 2.5 MG Oral Tablet [Femara]letrozole/tamoxifen

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Abstract PD2-01: Randomized phase 3 trial of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor positive, node positive early breast cancer: Final efficacy and…
Background The FACE trial was designed to evaluate the efficacy and safety of adjuvant letrozole (LET) versus anastrozole (ANA… 
2013
2013
Effects of femara and tamoxifen on proliferation of FM3A cells in culture.
In this study, antiproliferative effects of the selective estrogen receptor modulator Tamoxifen and the aromatase inhibitor… 
Review
2011
Review
2011
Approval summary: letrozole (Femara® tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: conversion of accelerated to full approval.
On April 30, 2010, the U.S. Food and Drug Administration converted letrozole (Femara®; Novartis Pharmaceuticals Corporation, East… 
2009
2009
0242 Cost effectiveness analysis of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive breast cancer
Review
2007
Review
2007
Femara® and the future: tailoring treatment and combination therapies with Femara
Long-term estrogen deprivation treatment for breast cancer can, in some patients, lead to the activation of alternate cellular… 
2006
2006
Letrozole (Femara) causes potent suppression of breast cancer tissue estrogen levels in the neoadjuvant setting.
10532 Background: Aromatase inhibitors of the third generation like letrozole, anastrozole and exemestane are known to suppress… 
2006
2006
Aromatase Inhibitors for Breast Cancer: Exemestane (Aromasin®), Anastrozole (Arimidex®), and Letrozole (Femara®)
  • J. Li
  • 2006
  • Corpus ID: 70550625
2001
2001
Letrozole (femara) is a more effective inhibitor of estrogen activity than tamoxifen: Evidence from a randomized phase III trial of 4 months preoperative endocrine therapy for postmenopausal women…
1999
1999
[Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer].
The study compares letrozole (Femara and aminoglutethimide (AG), a standard therapy for postmenopausal women with advanced breast… 
1997
1997
Letrozole (FEMARA®), a new potent, selective aromatase inhibitor (AI): Superior to another AI, aminoglutethimlde (AG), in postmenopausal women with advanced breast cancer (ABC), after relapse or…
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)